An ex vivo perfusion system emulating in vivo conditions in noncirrhotic and cirrhotic human liver

Journal of Pharmacology and Experimental Therapeutics

Volumn 342, Issue 3, 2012, Pages 730-741

  Schreiter, Thomas ^a   Marquitan, Guido ^a   Darnell, Malin ^b   Sowa, Jan Peter ^a   Bröcker Preuss, Martina ^a   Andersson, Tommy B ^b   Baba, Hideo A ^a   Furch, Marcus ^c   Arteel, Gavin E ^d   Mathé, Zoltan ^a   Treckmann, Jürgen ^a   Gerken, Guido ^a   Gieseler, Robert K ^a,c   Canbay, Ali ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Rodos BioTarget GmbH   (Germany)

^d University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILE ACID; BIOLOGICAL MARKER; DICLOFENAC; DRUG METABOLITE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GLUTAMATE DEHYDROGENASE; GLYCOGEN; LACTATE DEHYDROGENASE; LACTIC ACID; MIDAZOLAM; OXYGEN; PHENACETIN; UREA;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL DEATH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG SCREENING; DRUG TRANSFORMATION; EX VIVO PERFUSION SYSTEM; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER PERFUSION; MALE; PRIORITY JOURNAL;

ADULT; AGED; ALBUMINS; APOPTOSIS; BILE ACIDS AND SALTS; BIOLOGICAL MARKERS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GLUCOSE; GLYCOGEN; HUMANS; LACTIC ACID; LIVER; LIVER CIRRHOSIS; MALE; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; MIDDLE AGED; PERFUSION; UREA;

EID: 84865177276     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.194167     Document Type: Article

References (41)

1. Akashi Y, Miyazaki H, Yanagisawa J, and Nakayama F (1987) Bile acid metabolism in cirrhotic liver tissue-altered synthesis and impaired hepatic secretion. Clin Chim Acta 168:199-206.
2. Ali AM, Rossouw HC, Silove M, and Walt JG (2000) Development of an improved technique for the perfusion of the isolated caudal lobe of sheep liver. Exp Physiol 85:469-478.
3. Almenoff PL, Leavy J, Weil MH, Goldberg NB, Vega D, and Rackow EC (1989) Prolongation of the half-life of lactate after maximal exercise in patients with hepatic dysfunction. Crit Care Med 17:870-873. (Pubitemid 19233314)
4. Angulo P (2007) Obesity and nonalcoholic fatty liver disease. Nutr Rev 65:S57-S63.
5. Balmert SC, McKeel D, Triolo F, Gridelli B, Zeilinger K, Bornemann R, and Gerlach JC (2011) Perfusion circuit concepts for hollow-fiber bioreactors used as in vitro cell production systems or ex vivo bioartificial organs. Int J Artif Organs 34:410-421.
6. Bechmann LP, Jochum C, Kocabayoglu P, Sowa JP, Kassalik M, Gieseler RK, Saner F, Paul A, Trautwein C, Gerken G, et al. (2010) Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol 53:639-647.
7. Bernal W, Donaldson N, Wyncoll D, and Wendon J (2002) Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 359:558-563. (Pubitemid 34178437)
8. Bessems M, 't Hart NA, Tolba R, Doorschodt BM, Leuvenink HG, Ploeg RJ, Minor T, and van Gulik TM (2006) The isolated perfused rat liver: standardization of a time-honoured model. Lab Anim 40:236-246. (Pubitemid 44065221)
9. Bhatia SN, Balis UJ, Yarmush ML, and TonerM(1999) Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. FASEB J 13:1883-1900. (Pubitemid 29517619)
10. Bhogal RH, Hodson J, Bartlett DC, Weston CJ, Curbishley SM, Haughton E, Williams KT, Reynolds GM, Newsome PN, Adams DH, et al. (2011) Isolation of primary human hepatocytes from normal and diseased liver tissue: a one hundred liver experience. PLoS ONE 6:e18222.
11. Canbay A, Jochum C, Bechmann LP, Festag S, Gieseler RK, Yüksel Z, Lütkes P, Saner FH, Paul A, and Gerken G (2009) Acute liver failure in a metropolitan area in Germany: a retrospective study (2002-2008). Z Gastroenterol 47:807-813.
12. Cheng F, Theodorescu D, Schulman IG, and Lee JK (2011) In vitro transcriptomic prediction of hepatotoxicity for early drug discovery. J Theor Biol 290:27-36.
13. Dandri M, Volz TK, Lütgehetmann M, and Petersen J (2005) Animal models for the study of HBV replication and its variants. J Clin Virol 34 (Suppl 1):S54-S62. (Pubitemid 43197749)
14. Dutkowski P, de Rougemont O, and Clavien PA (2008) Machine perfusion for "marginal" liver grafts. Am J Transplant 8:917-924. (Pubitemid 351537756)
15. Elaut G, Papeleu P, Vinken M, Henkens T, Snykers S, Vanhaecke T, and Rogiers V (2006) Hepatocytes in suspension. Methods Mol Biol 320:255-263.
16. Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, and Canbay A (2011) Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128: 2436-2443.
17. Funatsu K, Ijima H, Nakazawa K, Yamashita Y, Shimada M, and Sugimachi K (2001) Hybrid artificial liver using hepatocyte organoid culture. Artif Organs 25:194-200. (Pubitemid 32852967)
18. Gebhardt R, Hengstler JG, Müller D, Glöckner R, Buenning P, Laube B, Schmelzer E, Ullrich M, Utesch D, Hewitt N, et al. (2003) New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab Rev 35:145-213. (Pubitemid 37048295)
19. Gerlach JC (2006) Bioreactors for extracorporeal liver support. Cell Transplant 15 (Suppl 1):S91-S103.
20. Gómez-Lechón MJ, Castell JV, and Donato MT (2008) An update on metabolism studies using human hepatocytes in primary culture. Expert Opin Drug Metab Toxicol 4:837-854.
21. Gómez-Lechón MJ, Donato T, Ponsoda X, and Castell JV (2003) Human hepatic cell cultures: in vitro and in vivo drug metabolism. Altern Lab Anim 31:257-265. (Pubitemid 36950597)
22. Groneberg DA, Grosse-Siestrup C, and Fischer A (2002) In vitro models to study hepatotoxicity. Toxicol Pathol 30:394-399. (Pubitemid 34556110)
23. Grosse-Siestrup C, Pfeffer J, Unger V, Nagel S, Witt C, Fischer A, and Groneberg DA (2002) Isolated hemoperfused slaughterhouse livers as a valid model to study hepatotoxicity. Toxicol Pathol 30:749-754. (Pubitemid 36015318)
24. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, et al. (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
25. Kmieć Z (2001) Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol 161:III-XIII, 1-151.
26. Krähenbühl L, Lang C, Lüdes S, Seiler C, Schäfer M, Zimmermann A, and Krähenbühl S (2003) Reduced hepatic glycogen stores in patients with liver cirrhosis. Liver Int 23:101-109.
27. Liew CY, Lim YC, and Yap CW (2011) Mixed learning algorithms and features ensemble in hepatotoxicity prediction. J Comput Aided Mol Des 25:855-871.
28. Lütgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, Pollok JM, Lohse AW, Petersen J, Urban S, et al. (2012) Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology 55:685-694.
29. Melgert BN, Olinga P, Weert B, Slooff MJ, Meijer DK, Poelstra K, and Groothuis GM (2001) Cellular distribution and handling of liver-targeting preparations in human livers studied by a liver lobe perfusion. Drug Metab Dispos 29:361-367. (Pubitemid 32275547)
30. Monbaliu D and Brassil J (2010) Machine perfusion of the liver: past, present and future. Curr Opin Organ Transplant 15:160-166.
31. Mueller D, Tascher G, Müller-Vieira U, Knobeloch D, Nuessler AK, Zeilinger K, Heinzle E, and Noor F (2011) In-depth physiological characterization of primary human hepatocytes in a 3D hollow-fiber bioreactor. J Tissue Eng Regen Med 5:e207-218.
32. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, and Degenhardt L (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378:571-583.
33. Pennington CR, Ross PE, and Bouchier IA (1977) Serum bile acids in the diagnosis of hepatobiliary disease. Gut 18:903-908. (Pubitemid 8230169)
34. Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, and Weitz J (2011) Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 253:453-469.
35. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, et al. (2004) Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901-912. (Pubitemid 39129297)
36. Taylor MJ and Baicu SC (2010) Current state of hypothermic machine perfusion preservation of organs: the clinical perspective. Cryobiology 60:S20-S35.
37. Thewes S, Reed HK, Grosse-Siestrup C, Groneberg DA, Meissler M, Schaller M, and Hube B (2007) Haemoperfused liver as an ex vivo model for organ invasion of Candida albicans. J Med Microbiol 56:266-270.
38. Vanwolleghem T, Libbrecht L, Hansen BE, Desombere I, Roskams T, Meuleman P, and Leroux-Roels G (2010) Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. J Hepatol 53:468-476.
39. Vogel T, Brockmann JG, and Friend PJ (2010) Ex-vivo normothermic liver perfusion: an update. Curr Opin Organ Transplant 15:167-172.
40. Watkins PB (2011) Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther 89:788-790.
41. Zeilinger K, Schreiter T, Darnell M, Söderdahl T, Lübberstedt M, Dillner B, Knobeloch D, Nüssler AK, Gerlach JC, and Andersson TB (2011) Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies. Tissue Eng Part C Methods 17:549-556.